What Is Gene Therapy? A Clear Guide To How It Works, Risks, And Real-World Uses (2026)

The table draws on the National Organization for Rare Disorders’ gene therapy FAQ and the NHGRI overview of gene therapy approaches.

What is gene therapy? It is a technology that uses genetic material, DNA and RNA, to treat or prevent disease. It may stop a disease from progressing, but it generally cannot correct damage that has already occurred.

Gene therapy is one part of the wider question of how is biotechnology used in medicine. This guide starts with what the treatment means for patients and decisions, then explains the mechanism behind it.

What gene therapy changes for patients

MD Anderson Cancer Center describes gene therapy as treating disease by modifying a patient’s DNA. For a patient, the useful question is how far that modification can reach, and for which problems.

Timing and existing damage

Gene therapy works on the cause of a disease, but it does not rewind the body. NORD notes that it might prevent progression but generally can’t correct damage that has already happened. NHGRI makes the same point for sickle cell disease: gene therapy will not reverse some complications, such as avascular necrosis.

This changes how people should plan. Someone with established complications should ask what will remain after treatment and what supportive care will still be needed. Expect stabilisation of the underlying condition, not restoration of tissue that has already been lost.

Who is most likely to be considered

Most gene therapy research currently focuses on patients with serious or life-threatening rare disorders and cancers, according to NORD. A common, mild condition is therefore unlikely to have a gene therapy option. A person with a rare inherited disorder or a cancer such as an aggressive blood cancer is more likely to find one, either as an approved product or in a trial.

Conditions treated today

Gene and cell therapies have been authorised for a growing number of conditions, but the list remains short, as the European consortium EuroGCT explains. The examples below show where treatment exists and how the choice is made.

Sickle cell disease

NHGRI states that gene therapy for sickle cell disease is available through FDA-approved therapies and through clinical trials. That gives patients two routes. An approved product has completed regulatory review, while a trial may offer an approach still under study. A specialist team can say which route fits a patient’s circumstances and what each involves.

Cancers and immune disorders

CAR T-cell therapy is used to treat certain kinds of aggressive blood cancers, according to EuroGCT. For severe combined immunodeficiency, gene therapy or combined cell and gene therapy may be appropriate when no suitable blood stem cell donor can be found. In that case the therapy serves as an alternative to a donor-based transplant, so it matters most when a donor search has failed.

Approved products

MD Anderson’s undated patient page states that at the time of writing only three FDA-approved gene therapies were available. Because the field is growing, a fixed count in any article goes out of date. Check the FDA’s approved cellular and gene therapy products list for the current position, and ask a treating team whether a listed product matches the diagnosis.

Risks and what to ask about

Gene therapy risks depend on the delivery method and on how little is yet known about long-term outcomes. MD Anderson cautions that a viral vector could regain its ability to cause infection, although viruses used as vectors are disarmed and carry low risks. It also says complications could arise from the highly intricate insertion process. NORD adds that more research is needed to understand the long-term effects of gene therapy.

These risks are best handled by asking specific questions, not by a general yes or no. Useful questions include:

• Which vector is used? A virus-based vector carries the infection-related risk described above, while a particle-based delivery system works differently.
• How is the therapy delivered? Direct injection or an intravenous infusion differs from a procedure that removes a patient’s cells, modifies them in a lab and returns them.
• How will long-term effects be followed? Because evidence on long-term effects is still developing, ask what monitoring will continue after treatment.
• Is this an approved product or a trial? Approved therapies and clinical trials sit at different stages of evidence, and the answer shapes how outcomes are tracked.

Cost, coverage and access

NORD attributes the high cost partly to research: conducting research and developing a safe and effective gene therapy is costly. A treatment built for a narrow patient group carries that cost into the final price, so patients should expect cost to be a real planning issue.

On coverage, NORD says that some FDA-approved gene therapies have been covered by some insurance companies. That is not a guarantee for every product or every plan, so confirm coverage with the insurer and the treating centre before treatment begins. People weighing how healthcare is adopting other new technologies can find broader context in AI In Healthcare Statistics: Key Trends, Impact, And What 2026 Data Reveals – Biolifetechnologies.

How gene therapy works

Gene therapy delivers genetic material into a patient’s cells so that the cells can make a working version of a missing or faulty product. EuroGCT notes that the approach relies on altering millions of cells to have a successful effect. That scale explains why delivery is the central engineering problem.

Delivery routes

MD Anderson describes two broad routes. In the first, the vector is injected or introduced intravenously into the patient’s tissue. In the second, a patient’s cells are exposed to the vector in a laboratory and then returned to the body.

Sickle cell disease illustrates the second route. NHGRI explains that stem cells are collected, an extra copy of a hemoglobin A gene, without the variant, is added to the stem cell, and the modified cells are returned to the body after the lab changes. Because the treatment adds a working gene rather than rewriting the original, it is described as gene addition.

CAR T-cell therapy follows a similar logic with a different aim. According to MD Anderson, it alters a patient’s T cells to turn them into killer cells that attack cancerous tumors.

Choosing a vector

A vector is the carrier that moves genetic material into cells. Viruses are the most common vectors because they are uniquely capable of infecting cells and transferring genes, according to MD Anderson. Researchers have also discovered how to use microscopic particles for delivery instead of viral vectors, which gives teams an alternative when a virus-based carrier is unsuitable.

The practical contrast is this. A viral vector is efficient at entering cells, but it brings the infection-related risk discussed earlier. A particle-based approach avoids that risk. For a closer look at one widely discussed viral vector, see AAV Gene Therapy: What It Is, How It Works, and What Patients Need To Know In 2026 – Biolifetechnologies.

Frequently asked questions